A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer

The efficacy of afatinib was inferior to cetuximab in patients with KRAS wild-type mCRC. In patients with KRAS-mutated tumours, disease control was modest with afatinib. Afatinib had a manageable safety profile.